Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women

Maturitas ◽  
1991 ◽  
Vol 13 (1) ◽  
pp. 87-88
Author(s):  
T. Fornander ◽  
L.E. Rutqvist ◽  
H.E. Sjoberg ◽  
L. Blomqvist ◽  
A. Mattsson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Bone Mineral ◽  
Adjuvant Tamoxifen ◽  
Mineral Density

Long-term adjuvant tamoxifen in early breast cancer: effect on bone mineral density in postmenopausal women.

1990 ◽  
Vol 8 (6) ◽  
pp. 1019-1024 ◽  
Author(s):  
T Fornander ◽  
L E Rutqvist ◽  
H E Sjöberg ◽  
L Blomqvist ◽  
A Mattsson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Bone Loss ◽  
Trabecular Bone ◽  
Bone Mineral ◽  
Postmenopausal Breast Cancer ◽  
Adjuvant Tamoxifen ◽  
Mineral Density ◽  
Long Term Treatment

The decrease in sex steroid hormone levels after the onset of menopause is associated with bone loss and subsequent osteoporosis. Tamoxifen has antiestrogenic properties and may thus theoretically decrease bone mineral density, particularly after long-term treatment. Bone mineral density (BMD) was assessed in 75 recurrence-free postmenopausal breast cancer patients included in a randomized trial of adjuvant tamoxifen (40 mg daily) for 2 or 5 years versus no adjuvant endocrine therapy. The measurements were done about 7 years after the initial randomization. BMD was measured with single-photon absorptiometry (SPA) at two levels of the distal forearm representing cortical and trabecular bone. The BMD was found to be similar among tamoxifen patients compared with the controls. For cortical bone, the BMD was 1.03 g/cm2 (95% confidence interval [Cl], 0.97 to 1.09) among tamoxifen patients and 1.03 g/cm2 (95% Cl, 0.96 to 1.11) in controls. For trabecular bone, the values were 0.74 g/cm2 (95% Cl, 0.70 to 0.79) and 0.73 g/cm2 (95% Cl, 0.68 to 0.79), respectively. The results thus did not indicate an accelerated postmenopausal bone loss with long-term adjuvant tamoxifen.

Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer

Maturitas ◽  
2010 ◽  
Vol 66 (3) ◽  
pp. 291-297 ◽  
Author(s):  
Xavier Nogues ◽  
Sonia Servitja ◽  
Maria Jesus Peña ◽  
Daniel Prieto-Alhambra ◽  
Rosa Nadal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Bone Mineral ◽  
Aromatase Inhibitors ◽  
Mineral Density

Changes in bone mineral density during 5 years of adjuvant exemestane therapy in postmenopausal women with early breast cancer.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e12003-e12003
Author(s):  
Akira Hirano ◽  
Hiroaki Inoue ◽  
Kaoru Ogura ◽  
Akinori Hattori ◽  
Hiroko Yukawa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Bone Mineral ◽  
Mineral Density

Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole

2013 ◽  
Vol 139 (6) ◽  
pp. 915-923 ◽  
Author(s):  
Matthias Kalder ◽  
Volker Ziller ◽  
Ioannis Kyvernitakis ◽  
Dana Knöll ◽  
Olaf Hars ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Bone Mineral ◽  
Mineral Density
Sign in / Sign up

Export Citation Format

Share Document